Mantle cell lymphoma: Report of the 2010 Mantle Cell Lymphoma Consortium Workshop

Michael E. Williams, Joseph M. Connors, Martin H. Dreyling, Randy D. Gascoyne, Brad S. Kahl, John P. Leonard, Oliver W. Press, Wyndham H. Wilson

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination. Although MCL is incurable with current therapies, with the exception of allogeneic stem cell transplant, recent advances are improving long-term outcomes in MCL. Intensive research has continued to focus on elucidating biological mechanisms of MCL, identifying new molecular targets, and optimizing existing therapies. Most recently, researchers have begun focusing on new areas such as epigenetics and microRNAs and their potential applications to MCL therapy. Advances across a broad spectrum of MCL research were presented at a recent MCL Workshop. This report provides an overview of the scientific highlights from the meeting and a framework for future research.

Original languageEnglish
Pages (from-to)24-33
Number of pages10
JournalLeukemia and Lymphoma
Issue number1
StatePublished - Jan 2011


  • Adoptive cellular therapy
  • Cell cycle
  • Immunotherapy
  • Mantle cell lymphoma
  • MicroRNA
  • Minimal residual disease (MRD)


Dive into the research topics of 'Mantle cell lymphoma: Report of the 2010 Mantle Cell Lymphoma Consortium Workshop'. Together they form a unique fingerprint.

Cite this